Zenas BioPharma, Inc.

Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company focused on immunology and inflammation therapies for autoimmune diseases. Its pipeline includes obexelimab, orelabrutinib, ZB021, ZB022, ZB002, ZB004, and partnered regional programs such as ZB001 in greater China.

−3 830,0 %

−3 777,4 %

+100,0 %

5.61

5.61

— Zenas BioPharma, Inc.
%
Lead immunology programs55% Core clinical and partnered assets centered on obexelimab and orelabrutinib for autoimmune and I&I diseases.
Early-stage pipeline20% Discovery and IND-enabling assets including ZB021 and ZB022 aimed at future clinical entry.
Other internal programs15% Additional proprietary I&I candidates such as ZB002 and ZB004 that may be advanced with partners.
Regional partnered programs10% Licensed or sublicensed programs such as ZB001/VRDN-001 in greater China.

Zenas primarily serves pharmaceutical partners, licensees, and collaboration counterparties rather than end patients...

  • Biopharma licensees and partnersprimary

    Companies such as BMS, Zai, Tenacia, and other collaborators that buy regional rights, development access, or royalty streams.

  • Future specialty prescriberssecondary

    Rheumatologists, immunologists, and other specialists who would prescribe approved I&I therapies.

  • Payers and health systemssecondary

    Insurers and healthcare systems that influence uptake through reimbursement and formulary access.

  • Clinical trial ecosystemprimary

    CROs, CMOs, and research sites that support development, manufacturing, and trial execution.

Zenas is headquartered in the United States and expects to build commercialization capabilities in the U.S...

  • •Headquartered in the United States
  • •Plans U.S. and Europe commercialization infrastructure
  • •BMS territory covers Japan, South Korea, Taiwan, Hong Kong, Singapore, Australia
  • •Greater China is a key partnered region for ZB001
  • •Clinical and supply chain activity depends on third-party global partners

Zenas is building an immunology-focused pipeline through product candidate acquisition, internal development, and...

01
Advance obexelimab toward late-stage and approval milestonesshort-term

It is the most advanced asset and the anchor for future commercialization and royalty economics.

02
Expand the pipeline with ZB021 and ZB022medium-term

New assets broaden the immunology platform and create future clinical optionality.

03
Use regional partnerships to monetize non-core geographiesmedium-term

Out-licensing can reduce capital needs while preserving upside through royalties and milestones.

04
Prepare commercial infrastructure in the U.S. and Europemedium-term

Direct commercialization would allow Zenas to capture more value if lead assets are approved.

Zenas faces the typical risks of a clinical-stage biopharma company: clinical failure, regulatory setbacks, and the...

critical

Clinical development failure

Pipeline assets may not show sufficient efficacy or safety to advance or win approval.

Scope
All programs, especially obexelimab, ZB021, and ZB022
Materiality
high
high

Capital raising and dilution

The company expects to fund operations externally until meaningful product revenue exists.

Scope
Corporate-wide
Materiality
high
high

Manufacturing and supply disruption

Clinical and future commercial supply depends on third-party CMOs and partners.

Scope
Obexelimab, orelabrutinib, ZB021, ZB022
Materiality
high
high

Partner concentration and regional execution

Out-licensed territories and sublicenses reduce direct control over development and commercialization.

Scope
BMS territory, greater China, other partnered regions
Materiality
medium
medium

Cybersecurity and geopolitical disruption

Clinical data, remote work, and third-party systems can be disrupted by attacks or conflicts.

Scope
Global operations and trial infrastructure
Materiality
medium
License and collaboration revenue recognition
Can create volatile revenue unrelated to current operating scale
Accrued research and development expenses
Affects quarterly R&D expense and operating loss
Fair value measurement of financing instruments
Can affect reported equity and non-cash gains or losses
Impairment and valuation of in-licensed programs
Potential write-downs if programs underperform

MEKO

MEKO.ST · Consumer Discretionary

Xeris Biopharma Holdings, Inc.

XERS · Pharmaceutical Preparations

Bufab

BUFAB.ST · Industrials

Apotea

APOTEA.ST · Consumer Staples

Zentalis Pharmaceuticals, Inc.

ZNTL · Pharmaceutical Preparations

Knowit

KNOW.ST · Technology

: 29.4.2026